A possible shift in licensing strategy

I saw this in the recent edition of Bioshares. It looks like a subtle, and sensible, shift in licensing strategy for 210 which could ultimately convert into much more shareholder value. I like this move as it makes sense given the parallel development pathway. Anyway, DYOR and GLTA

"Bionomics had previously planned to license BNC210 within nine months of the release of the Phase II GAD trial results (see Bioshares 666). However, the company has now adjusted its position on licencing and has not decided at which point it will license this asset, as well as considering whether it can exclude certain market indications from any licensing transaction. What it is doing is to open up parallel paths so that it can to leave open multiple deal possibilities in discussions with potential partners."